We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Developed for Histoplasmosis Diagnosis

By LabMedica International staff writers
Posted on 27 Jan 2011
An immunoassay, using purified deglycosylated antigen, has been developed to diagnose different manifestations of the fungal disease histoplasmosis. More...


The enzyme-linked immunosorbent assay (ELISA) detects antibodies to Histoplasma capsulatum, the causative agent of histoplasmosis, using metaperiodate treated purified histoplasmin (ptHMIN), the specific antigen of this fungus.

To evaluate the ELISA test clinical serum samples were selected randomly from the Immunodiagnostic Section Serum Bank, Laboratory of Mycology, Institute of Clinical Research Evandro Chagas, (Fiocruz; Rio de Janeiro, Brazil). Forty-four sera samples were tested from homologous histoplasmosis and 35 sera samples from other cases of mycoses. These included seven with paraccocidioidomycosis; eight for each of the following: aspergillosis sporotrichosis, and cryptococcosis cases, and four from coccidioidomycosis patients. Additionally, 36 negative control sera from healthy donors were collected and tested.

The results of the assay showed that the optical densities (ODs) were significantly higher in sera from 44 patients with histoplasmosis than in heterologous-infected samples evaluated. Differences in the means and comparisons of parameters indicate that the test effectively discriminates between negative and positive samples. The distribution of OD values varied in the clinical groups, but no statistical differences were found between them. The OD values are an indication of antibody levels in the patients' sera.

The overall test specificity was 96%, with sensitivities of 100% in acute disease, 90% in chronic disease, 86% in disseminated disease co-infected with Human Immunodeficiency Virus (HIV), 89% in disseminated infection in individuals without HIV infection, and 100% in mediastinal histoplasmosis. The authors of the study concluded that the high specificities, sensitivities, and simplicity of the ELISA support further development of a deglycosylated HMIN ELISA for clinical use and for monitoring the humoral immune response during therapy in patients with chronic and disseminated histoplasmosis.

Histoplasmosis is a disease caused when airborne spores of the fungus H. capsulatum are inhaled into the lungs, the primary infection site. This microscopic fungus, which is found throughout the world in river valleys and soil where bird or bat droppings accumulate, is released into the air when soil is disturbed by plowing fields, sweeping chicken coops, or digging holes. The clinical disease generally ranges from mild influenza-like illnesses to progressive, disseminated disease, which manifests mostly in immunocompromised individuals. The study was published on line on January 4, 2010, in the open access journal Microbiology Research.

Related Links:

Institute of Clinical Research Evandro Chagas





Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.